Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
OwnerWendell A. Lim, Milos Simic +3inventors
InventorsWendell A. Lim, Milos Simic, Hideho Okada, Joseph H. Choe, Payal B. Watchmaker
Life of this patent
Estimating the term…
Abstract
Provided herein is a cell comprising a recombinant nucleic acid encoding a transmembrane protein that has an extracellular binding domain that specifically binds to a brain-selective extracellular antigen, e.g., MOG, CDH10, PTPRZ1 or NRCAM, wherein the cell does not comprise a nucleic acid encoding an antigen-specific therapeutic that binds to a killing antigen expressed by a glioblastoma.
Claims27
A cell comprising a recombinant nucleic acid encoding a transmembrane protein that has an extracellular binding domain that specifically binds to a brain-selective extracellular antigen, wherein the cell does not comprise a nucleic acid encoding an antigen-specific therapeutic that binds to a killing antigen expressed by a glioblastoma.
The cell of any of any prior claim, wherein the transmembrane protein is a binding-triggered transcriptional switch and the cell further comprises a nucleic acid comprising:
- (i) a coding sequence encoding a therapeutic protein and (ii) a regulatory sequence, wherein the regulatory sequence is operably linked to the coding sequence and is responsive to activation of the a binding-triggered transcriptional switch.
The system of any prior claim, wherein the binding-triggered transcriptional switch is one or more polypeptides that undergo proteolytic cleavage upon binding to the brain-selective extracellular antigen to release a gene expression regulator that activates transcription of the therapeutic protein.
Dependencies are inferred from the claim text.